Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares gapped up prior to trading on Thursday . The stock had previously closed at $42.47, but opened at $42.53. Agios Pharmaceuticals shares last traded at $43.92, with a volume of 188,615 shares traded.

Several research analysts have recently commented on the company. Canaccord Genuity reissued a “hold” rating and issued a $50.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, June 9th. Vetr lowered Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $68.42 target price on the stock. in a research report on Tuesday, June 7th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Monday, April 25th. Zacks Investment Research lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 26th. Finally, SunTrust Banks Inc. upped their target price on Agios Pharmaceuticals from $57.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, May 18th. Six equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Agios Pharmaceuticals has a consensus rating of “Buy” and an average target price of $69.67.

The firm’s 50 day moving average is $47.31 and its 200-day moving average is $45.75. The stock’s market cap is $1.63 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.18. During the same quarter last year, the business posted ($0.13) earnings per share. The company earned $31.30 million during the quarter, compared to analysts’ expectations of $20.94 million. The company’s revenue for the quarter was down 8.5% on a year-over-year basis. Analysts forecast that Agios Pharmaceuticals Inc. will post ($3.46) earnings per share for the current year.

In related news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $41.88, for a total value of $104,867.52. Following the completion of the transaction, the director now directly owns 125,921 shares in the company, valued at $5,273,571.48. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Scott Biller sold 27,500 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $65.00, for a total value of $1,787,500.00. Following the completion of the transaction, the insider now owns 81,376 shares of the company’s stock, valued at $5,289,440. The disclosure for this sale can be found here.

Other hedge funds have bought and sold shares of the company. Jennison Associates LLC boosted its stake in Agios Pharmaceuticals by 170.6% in the fourth quarter. Jennison Associates LLC now owns 430,085 shares of the biopharmaceutical company’s stock worth $27,921,000 after buying an additional 271,142 shares in the last quarter. BB Biotech AG boosted its stake in Agios Pharmaceuticals by 2.4% in the fourth quarter. BB Biotech AG now owns 2,159,921 shares of the biopharmaceutical company’s stock worth $140,222,000 after buying an additional 50,000 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in Agios Pharmaceuticals by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 17,325 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 86 shares in the last quarter. GAM Holding AG boosted its stake in Agios Pharmaceuticals by 210.9% in the fourth quarter. GAM Holding AG now owns 45,700 shares of the biopharmaceutical company’s stock worth $2,967,000 after buying an additional 31,000 shares in the last quarter. Finally, Columbia Wanger Asset Management LLC boosted its stake in Agios Pharmaceuticals by 11.4% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 436,994 shares of the biopharmaceutical company’s stock worth $28,370,000 after buying an additional 44,861 shares in the last quarter.

Agios Pharmaceuticals, Inc (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.